Literature DB >> 29986862

Access to new drugs for rare disorders in Canada.

Nigel S Rawson1, John Adams2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29986862      PMCID： PMC6041252          DOI： 10.1503/cmaj.69340

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  We need a "made in Canada" orphan drug framework.

Authors:  Hugh J McMillan; Craig Campbell
Journal:  CMAJ       Date:  2017-10-16       Impact factor: 8.262

2.  What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?

Authors:  Nigel Rawson
Journal:  J Popul Ther Clin Pharmacol       Date:  2017-12-01

3.  Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?

Authors:  Nigel Sb Rawson; John Adams
Journal:  Clinicoecon Outcomes Res       Date:  2017-11-22

4.  Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.

Authors:  Nigel S B Rawson
Journal:  Orphanet J Rare Dis       Date:  2017-03-23       Impact factor: 4.123

Review 5.  Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.

Authors:  Trevor Richter; Ghayath Janoudi; William Amegatse; Sandra Nester-Parr
Journal:  Orphanet J Rare Dis       Date:  2018-02-01       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.